πŸ‡ΊπŸ‡Έ FDA
Patent

US 11820826

Anti-NPR1 antibodies and uses thereof

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 11820826 (Anti-NPR1 antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K45/06, A61K9/0019